Trial Profile
A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Firibastat (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms QUID-HF
- Sponsors Quantum Genomics
- 11 Oct 2018 Status changed from recruiting to discontinued.
- 26 Sep 2018 This trial has been Discontinued in Czech Republic, according to European Clinical Trials Database
- 19 Jul 2018 Planned End Date changed from 1 Jul 2018 to 31 Dec 2018.